Seven years after listing, Medicilon has kept building depth as innovative drug sector gathered pace. Over those seven years, the honors that have come its way — from the choices clients make to recognition from the industry, from technical breakthroughs to compliant delivery — are not isolated labels but long-term proof of one capability: one-stop preclinical service. At this seventh anniversary, why does the industry keep trusting Medicilon, and why do its clients stay?
Chosen by Clients: Trust Through Delivery
For a CRO, client trust is the highest commendation there is. Medicilon runs drug discovery, CMC, preclinical studies, and regulatory filing as one integrated preclinical service, giving global innovative drug companies stable, professional, and efficient support.
01 From Target to IND: One-Stop Delivery
The one-stop preclinical platform connects the whole chain from Target to IND: modules hand off without seams, data move between them, and the communication barriers and data gaps of coordinating several vendors disappear — while multi-country filings stay supported. To date, Medicilon has supported 43 complete IND packages to clinical approval.
They include Nanolattix Group ‘s ADC T320, filed and approved in China, the US, and Australia; Gluetacs Therapeutics’s three degraders — GT919, GT929, and GT818 — each filed and approved in both China and the US; and Shanghai Yizhong Pharma’s YXC-001 and YXC-002, whose approvals brought Medicilon’s pharmaceutical and preclinical teams an Excellence in Partnership Award from the client. Biotime Biotechnology’s BIOT-006, Wayne Biotech’s WBD156, Yuyao Biotech’s YY201 tablets, and HBOW Biotech’s NC527-X have likewise been filed and approved in both China and the US on the Medicilon’s platform.
02 Holding the Dates: Ahead of Critical Milestones
Faced with tight timelines for new drug programs, the Medicilon team flexibly allocated manpower and resources, delivering milestones with exceptional execution. RayThera honored Medicilon team with its Outstanding Partner Award in recognition of our dedicated FTE team, who worked nonstop through holidays to shorten the timeline and deliver R&D ahead of schedule. ACEA Pharma sent a letter of commendation for the cross-departmental collaboration: during the emergency development of ormutrelvir sodium, a world-first dual-target oral COVID-19 drug, Medicilon advanced process scale-up, toxicology sample preparation and pharmacokinetic studies in parallel, securing precious time to accelerate the program.
03 Cracking the Hard Problems: Frontier Bottlenecks
Where frontier targets and new molecular modalities offer no mature reference protocol, the Medicilon’s teams redesign experiments themselves and build dedicated evaluation systems. Leadtac gave Medicilon’s DMPK team a special award for getting around the pain points of PROTAC molecules — large molecular weight, hard developability assessment. Immunophage gave Medicilon’s efficacy team a Best Partner Award for an MCAO modeling protocol that underpinned IPG7236, the first CCR small-molecule antagonist in the world to enter the clinic. Hexin Biotech gave Medicilon’s CMC team an Outstanding Partner Award for solving XY003’s extremely low solubility and complex formulation. Tasly thanked the Medicilon’s team for a dedicated PBC evaluation system and high-standard efficacy work on TSL2402 tablets.
04 Global Collaboration: A Long-Term Community of Growth
Medicilon’s relationships are moving from single-project delivery toward pipeline collaboration and long-term symbiosis. In China, it serves Hengrui Pharma, Yangtze River Pharmaceutical Group, Guangzhou Baiyunshan Pharmaceutical Holdings, Shanghai Pharmaceuticals, Livzon Pharmaceutical Group, China Resources Pharmaceutical Group, CSPC Pharmaceutical Group, and Huadong Medicine. Awards from clients include Jemincare’s Outstanding Performance Award, Regor Therapeutics’ Best Partner Award, ABM Therapeutics’ Best Service Team Award, MindRank’s Outstanding Team Award, SicaGene’s Best Partner Award, Jingxin Pharmaceutical’s Outstanding Contribution Team Award, and Gyre Pharmaceuticals’ Toxicology Pioneer Award. The Hengrui relationship spans 15 years across small nucleic acids, antibodies, peptides, ADCs, and PROTACs. In ADC, Medicilon ran preclinical work for MediLink Therapeutics’ YL201 and YL202 and contributed to payload R&D on the TMALIN platform, earning a Best Collaboration Award.
Globally, clients span the US, Europe, Japan, and Korea, among them Takeda (more than 15 years of partnership), Johnson & Johnson, GSK, Roche, Gilead Sciences, Novartis, Merck, AstraZeneca, and Lilly. Awards include Roche R&D Center China’s Most Valuable Partner Award, Millennium’s Three-Year Outstanding Partner Award, Sunovion’s Outstanding Achievement Award, Sepracor’s Excellence in R&D Award, and Eluciderm’s Excellence in Service Award. RayThera’s award appears above.
Partnership runs both ways: Medicilon gave Revolution Medicines an Outstanding Client Award for its pioneering pan-KRAS work and for what the two have reached together over years of joint effort.
Recognized by the Industry: Setting the Benchmark
Since listing, Medicilon has been named to Yaozh.com’s China CRO Excellence Brand Top 20 for seven consecutive years and to the PDI Conference’s China Pharmaceutical CRO Top 20 for seven consecutive years; it also appears in the CMC-CHINA Preclinical CRO Top 25 and the FNS101 Top 100 Future Pharma New Species. Among its titles: Most Satisfied CRO of the Year; Top 10 Innovative Drug Service Institutions at the Drug Innovation for Public Good Awards; Most Influential CXO on the China Biopharmaceutical Industry Value List; China Pharma R&D Top 50; Shanghai Hard-Tech Enterprise Top 100; STAR Market Hard-Tech Leader; and the Golden Bull STAR Award.
On ESG, the company ranks in the Top 10 for ESG Competitiveness among Chinese listed pharmaceutical companies, and its Wind ESG rating rose to AA in 2026, with ESG principles embedded in compliance, quality, governance, and R&D. In the capital markets it has won the Listed Company Excellence in Investor Relations Award and the STAR Market Hard-Tech Investment Value Award. These honors follow from the commitment to one-stop preclinical services, global delivery, and a high-standard compliance system.
Built on Platforms: Technology First
Behind the honors is platform capability built over years. Medicilon is recognized as a Shanghai High-Tech Enterprise, a Science and Technology Little Giant, a Specialized, Refined, Distinctive and Innovative enterprise, a Shanghai Municipal Enterprise Technology Center, and a Shanghai Innovative Enterprise Headquarters; it holds designations as a Shanghai R&D Public Service Platform, a Pudong New Area Enterprise R&D Institution, and a postdoctoral workstation.
Its subsidiary Medicilon Preclinical Research has built four municipal-level specialized platforms: non-human primate safety evaluation, isotope-labeled drug metabolism, protein crystallography-based drug screening, and nucleic acid drug preclinical research — and maintains an international-standard technology matrix across safety assessment, antibody R&D, pharmacokinetics, novel formulations, and pharmacodynamic evaluation, taking on the R&D challenges of frontier targets and novel drugs.
Trust takes root in a shared road; it is the echo of a journey made together.
Seven years listed — thank you for the confidence, and let us go further together. Every honor comes from client trust, from partners’ support, from industry recognition, and from the commitment of everyone at Medicilon. Innovation does not rest, and Medicilon will keep joining hands across the industry to help more innovative drugs reach the world.
